{"organizations": ["Hercules Technology", "Immune Pharmaceuticals"], "uuid": "2fbbeae1472cc75d0073295ab10f7e8747aad8e9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530609?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Hercules Technology grants $4.5mm loan to Immune Pharmaceuticals; $5mm more available", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Hercules Technology grants $4.5mm loan to Immune Pharmaceuticals; $5mm more available", "spam_score": 0.0, "site_type": "news", "published": "2015-08-06T02:40:00.000+03:00", "replies_count": 0, "uuid": "2fbbeae1472cc75d0073295ab10f7e8747aad8e9"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530609?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Hercules Technology grants $4.5mm loan to Immune Pharmaceuticals; $5mm more available", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Hercules Technology grants $4.5mm loan to Immune Pharmaceuticals ; $5mm more available Deal Date: Jul-01-2015 / Deal # 201530609 Executive Summary \nHercules Technology Growth Capital issued Immune Pharmaceuticals Inc. (treatments for cancer and inflammatory diseases) a $4.5mm term loan, with an additional $5mm available to the company before June 15, 2016, subject to certain clinical milestones and other events. The loan carries interest at a rate that is the greater of 10% and the prime rate plus 5.25%, and is payable interest-only for the first 18 months.", "external_links": [], "published": "2015-08-06T02:40:00.000+03:00", "crawled": "2015-08-06T14:43:49.487+03:00", "highlightTitle": ""}